Does the media favor RARE or NUVL?

In the previous week, Ultragenyx Pharmaceutical had 8 more articles in the media than Nuvalent. MarketBeat recorded 9 mentions for Ultragenyx Pharmaceutical and 1 mentions for Nuvalent. Ultragenyx Pharmaceutical's average media sentiment score of 0.78 beat Nuvalent's score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RARE or HALO?

In the previous week, Halozyme Therapeutics had 2 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 11 mentions for Halozyme Therapeutics and 9 mentions for Ultragenyx Pharmaceutical. Halozyme Therapeutics' average media sentiment score of 1.23 beat Ultragenyx Pharmaceutical's score of 0.78 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RARE or CYTK?

In the previous week, Cytokinetics had 11 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 20 mentions for Cytokinetics and 9 mentions for Ultragenyx Pharmaceutical. Cytokinetics' average media sentiment score of 0.79 beat Ultragenyx Pharmaceutical's score of 0.78 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 14 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PTGX or RARE?

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 10 mentions for Protagonist Therapeutics and 9 mentions for Ultragenyx Pharmaceutical. Protagonist Therapeutics' average media sentiment score of 1.57 beat Ultragenyx Pharmaceutical's score of 0.78 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ultragenyx Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RARE or SYRE?

In the previous week, Spyre Therapeutics had 2 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 11 mentions for Spyre Therapeutics and 9 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.78 beat Spyre Therapeutics' score of 0.77 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ultragenyx Pharmaceutical (RARE) Competitors

$25.81 +0.79 (+3.16%)

Closing price 04:00 PM Eastern

Extended Trading

$27.18 +1.38 (+5.33%)

As of 06:20 PM Eastern

Compare

RARE vs. NUVL, HALO, CYTK, PTGX, and SYRE

Should you buy Ultragenyx Pharmaceutical stock or one of its competitors? MarketBeat compares Ultragenyx Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ultragenyx Pharmaceutical include Nuvalent (NUVL), Halozyme Therapeutics (HALO), Cytokinetics (CYTK), Protagonist Therapeutics (PTGX), and Spyre Therapeutics (SYRE). These companies are all part of the "biotechnology" industry.

How does Ultragenyx Pharmaceutical compare to Nuvalent?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Nuvalent (NASDAQ:NUVL) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 5.0% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Ultragenyx Pharmaceutical had 8 more articles in the media than Nuvalent. MarketBeat recorded 9 mentions for Ultragenyx Pharmaceutical and 1 mentions for Nuvalent. Ultragenyx Pharmaceutical's average media sentiment score of 0.78 beat Nuvalent's score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ultragenyx Pharmaceutical currently has a consensus target price of $57.94, indicating a potential upside of 124.49%. Nuvalent has a consensus target price of $127.73, indicating a potential upside of 3.04%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, equities analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Nuvalent has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Nuvalent's return on equity of -40.11% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Nuvalent	N/A	-40.11%	-35.43%

Nuvalent has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Nuvalent is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.78	-$575M	-$6.11	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Summary

Ultragenyx Pharmaceutical beats Nuvalent on 10 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Halozyme Therapeutics?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Halozyme Therapeutics has a net margin of 23.13% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Halozyme Therapeutics' return on equity of 187.91% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Halozyme Therapeutics	23.13%	187.91%	21.92%

Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Ultragenyx Pharmaceutical presently has a consensus price target of $57.94, indicating a potential upside of 124.49%. Halozyme Therapeutics has a consensus price target of $81.60, indicating a potential downside of 1.96%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54

Halozyme Therapeutics has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.78	-$575M	-$6.11	N/A
Halozyme Therapeutics	$1.40B	7.07	$316.89M	$2.78	29.94

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Halozyme Therapeutics had 2 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 11 mentions for Halozyme Therapeutics and 9 mentions for Ultragenyx Pharmaceutical. Halozyme Therapeutics' average media sentiment score of 1.23 beat Ultragenyx Pharmaceutical's score of 0.78 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Halozyme Therapeutics beats Ultragenyx Pharmaceutical on 12 of the 17 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Cytokinetics?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

In the previous week, Cytokinetics had 11 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 20 mentions for Cytokinetics and 9 mentions for Ultragenyx Pharmaceutical. Cytokinetics' average media sentiment score of 0.79 beat Ultragenyx Pharmaceutical's score of 0.78 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	14 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ultragenyx Pharmaceutical has a net margin of -91.03% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Cytokinetics	-784.02%	N/A	-52.86%

Ultragenyx Pharmaceutical currently has a consensus target price of $57.94, indicating a potential upside of 124.49%. Cytokinetics has a consensus target price of $99.90, indicating a potential upside of 27.08%. Given Ultragenyx Pharmaceutical's higher probable upside, research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95

Ultragenyx Pharmaceutical has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.78	-$575M	-$6.11	N/A
Cytokinetics	$88.04M	111.10	-$784.96M	-$6.84	N/A

Summary

Ultragenyx Pharmaceutical beats Cytokinetics on 9 of the 17 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

Protagonist Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	189.79	-$130.15M	-$1.81	N/A
Ultragenyx Pharmaceutical	$673M	3.78	-$575M	-$6.11	N/A

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 10 mentions for Protagonist Therapeutics and 9 mentions for Ultragenyx Pharmaceutical. Protagonist Therapeutics' average media sentiment score of 1.57 beat Ultragenyx Pharmaceutical's score of 0.78 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ultragenyx Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ultragenyx Pharmaceutical has a net margin of -91.03% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Protagonist Therapeutics has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Protagonist Therapeutics presently has a consensus target price of $123.00, indicating a potential downside of 9.43%. Ultragenyx Pharmaceutical has a consensus target price of $57.94, indicating a potential upside of 124.49%. Given Ultragenyx Pharmaceutical's higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Protagonist Therapeutics beats Ultragenyx Pharmaceutical on 11 of the 17 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Spyre Therapeutics?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Spyre Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.78	-$575M	-$6.11	N/A
Spyre Therapeutics	$890K	10,369.02	-$155.20M	-$2.08	N/A

Ultragenyx Pharmaceutical presently has a consensus target price of $57.94, suggesting a potential upside of 124.49%. Spyre Therapeutics has a consensus target price of $101.42, suggesting a potential downside of 3.36%. Given Ultragenyx Pharmaceutical's higher possible upside, research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Ultragenyx Pharmaceutical has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.03, meaning that its share price is 203% more volatile than the broader market.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Spyre Therapeutics had 2 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 11 mentions for Spyre Therapeutics and 9 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.78 beat Spyre Therapeutics' score of 0.77 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Spyre Therapeutics' return on equity of -42.88% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Summary

Spyre Therapeutics beats Ultragenyx Pharmaceutical on 10 of the 16 factors compared between the two stocks.

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RARE vs. The Competition

Export

Metric	Ultragenyx Pharmaceutical	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.54B	$3.56B	$6.80B	$13.02B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-4.22	7.36	279.72	25.54
Price / Sales	3.78	1,274.64	648.69	115.96
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	-31.10	17.08	11.12	6.36
Net Income	-$575M	-$12.52M	$3.48B	$347.58M
7 Day Performance	-0.65%	2.52%	2.58%	3.16%
1 Month Performance	-22.89%	-5.36%	-2.79%	-2.06%
1 Year Performance	-9.31%	51.37%	64.28%	21.19%

Ultragenyx Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RARE Ultragenyx Pharmaceutical	3.6654 of 5 stars	$25.81 +3.2%	$57.94 +124.5%	-12.0%	$2.54B	$673M	N/A	1,371	News Coverage Earnings Report Analyst Forecast
NUVL Nuvalent	1.7148 of 5 stars	$123.96 flat	$127.73 +3.0%	N/A	$9.79B	N/A	N/A	40	Upcoming Earnings
HALO Halozyme Therapeutics	3.7918 of 5 stars	$82.27 -0.3%	$81.60 -0.8%	+39.4%	$9.79B	$1.40B	29.59	390	Positive News Upcoming Earnings
CYTK Cytokinetics	3.7292 of 5 stars	$76.45 -0.9%	$99.90 +30.7%	+108.4%	$9.60B	$88.04M	N/A	250	Upcoming Earnings
PTGX Protagonist Therapeutics	1.5831 of 5 stars	$132.28 -3.2%	$123.00 -7.0%	+145.7%	$8.79B	$46.02M	N/A	120	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RARE) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. NUVL, HALO, CYTK, PTGX, and SYRE

How does Ultragenyx Pharmaceutical compare to Nuvalent?

Summary

How does Ultragenyx Pharmaceutical compare to Halozyme Therapeutics?

Summary

How does Ultragenyx Pharmaceutical compare to Cytokinetics?

Summary

How does Ultragenyx Pharmaceutical compare to Protagonist Therapeutics?

Summary

How does Ultragenyx Pharmaceutical compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. NUVL, HALO, CYTK, PTGX, and SYRE

How does Ultragenyx Pharmaceutical compare to Nuvalent?

Which has more risk and volatility, RARE or NUVL?

Do insiders & institutionals hold more shares of RARE or NUVL?

Does the media favor RARE or NUVL?

Do analysts rate RARE or NUVL?

Is RARE or NUVL more profitable?

Which has stronger earnings and valuation, RARE or NUVL?

Summary

How does Ultragenyx Pharmaceutical compare to Halozyme Therapeutics?

Is RARE or HALO more profitable?

Which has more volatility and risk, RARE or HALO?

Do analysts rate RARE or HALO?

Which has better valuation and earnings, RARE or HALO?

Do insiders and institutionals hold more shares of RARE or HALO?

Does the media refer more to RARE or HALO?

Summary

How does Ultragenyx Pharmaceutical compare to Cytokinetics?

Do insiders & institutionals hold more shares of RARE or CYTK?

Which has more volatility & risk, RARE or CYTK?

Does the media refer more to RARE or CYTK?

Is RARE or CYTK more profitable?

Do analysts rate RARE or CYTK?

Which has higher earnings & valuation, RARE or CYTK?

Summary

How does Ultragenyx Pharmaceutical compare to Protagonist Therapeutics?

Which has better earnings and valuation, PTGX or RARE?

Does the media favor PTGX or RARE?

Is PTGX or RARE more profitable?

Do institutionals and insiders believe in PTGX or RARE?

Which has more risk and volatility, PTGX or RARE?

Do analysts rate PTGX or RARE?

Summary

How does Ultragenyx Pharmaceutical compare to Spyre Therapeutics?

Which has preferable earnings and valuation, RARE or SYRE?

Do analysts recommend RARE or SYRE?

Which has more risk & volatility, RARE or SYRE?

Do institutionals & insiders hold more shares of RARE or SYRE?

Does the media favor RARE or SYRE?

Is RARE or SYRE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools